CCCC FY 2021 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+37.9% YoY

Gross Profit

$46M100.0% margin

Operating Income

-$82M-179.4% margin

Net Income

-$84M-183.2% margin

EPS (Diluted)

$-1.82

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$88M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$507M

Total Liabilities

$117M

Stockholders' Equity

$390M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$33M	+37.9%
Gross Profit	$46M	-$45M	+201.2%
Operating Income	-$82M	-$60M	-35.9%
Net Income	-$84M	-$66M	-26.5%